



Comprehensive separation and quantitation of phyto-, semi-synthetic, and synthetic cannabinoids by LC-MS/MS

Justin L. Poklis¹, Kimberly N. Karin¹, Alaina K. Holt², Sean Orlowicz³, Adrian M. Taylor⁴, Linda Prensaman⁵, Craig M. Butt⁵, Michelle R. Peace^{1,2}

¹Department of Pharmacology and Toxicology, VCU;

²Department of Forensic Science, VCU; ³Phenomenex, USA;

⁴SCIEX, Canada; ⁵SCIEX, USA

This technical note demonstrates a robust LC-MS/MS method for the separation and quantitation of 12 cannabinoids in commercial vape e-liquids. Using the SCIEX QTRAP 6500+ system coupled with a Phenomenex Kinetex C18 column, chromatographic resolution was achieved for several challenging cannabinoid isomers including Δ^8 -THC, Δ^9 -THC, exo-THC, cannabichromene, cannabidiol, acetylated THC derivatives, and hexahydrocannabinol isomers [Figure 1]. A five-day validation study demonstrated good linearity with all calibration curves showing $r^2 \geq 0.996$. The method was applied to 25 commercially available e-liquids, revealing substantial diversity in the cannabinoid composition and highlighting the value of selective, reliable analytical methods to accurately characterize these highly complex vape products.

Key benefits of cannabinoid analysis using the SCIEX QTRAP 6500+ system

- **Differentiate legacy and emerging cannabinoids with confidence** Chromatographic resolution of key cannabinoid isomers and analogs was achieved using the Phenomenex Kinetex C18 column
- **Reliable quantitative results.** Good analytical performance demonstrated across a 5-day validation study including carry-over, calibration curve linearity and quality control (QC) accuracy and bias
- **Comprehensive characterization of commercial vape products.** The method was applied to 25 e-liquids demonstrating a diverse cannabinoid profile




Figure 1. Total ion chromatograms (TICs) showing the cannabinoid composition of "Thai Chi" and "Gorilla Glue" vaping e-liquids.

Introduction

The use of electronic cigarettes and vaping devices to deliver cannabinoids has expanded rapidly over the past decade, transforming both the legal cannabis and illicit drug markets. Although vaping was initially promoted as an alternative to combustible nicotine products, these devices have increasingly been adapted for the delivery of $\Delta 9$ -tetrahydrocannabinol ($\Delta 9$ -THC), cannabidiol (CBD), and the growing array of semi-synthetic and synthetic cannabinoids. Regulatory changes, including the 2018 U.S. Agricultural Improvement Act (the “Farm Bill”), facilitated the emergence of a largely unregulated market of hemp-derived cannabinoid vaping products, including $\Delta 8$ -THC, $\Delta 6a,10a$ -THC, hexahydrocannabinol (HHC), tetrahydrocannabiphorol (THCP), THC-O-acetates, and other analogs synthesized from CBD.^{1,2} Although some of these compounds occur naturally in cannabis or hemp, they are typically present at trace concentrations and are marketed as legal alternatives despite limited pharmacological and toxicological evaluation. Reported adverse effects include hallucinations, sedation, vomiting, and/or seizures.^{3,4}

Cannabinoid vaping products often contain high concentrations (>40%) of active compounds together with solvents, terpenes, flavoring agents, and carrier liquids such as propylene glycol, vegetable glycerin, and medium-chain triglycerides. Characterizing the cannabinoid profile of vaping products is important because a survey of U.S. users indicated that cannabinoids are the most frequently vaped drugs other than nicotine.⁵ Products may also contain complex mixtures of positional isomers, acetylated derivatives, hydrogenated cannabinoids, and unintended reaction byproducts arising from poorly controlled synthetic processes.¹ This increasing chemical diversity presents significant analytical challenges and to monitor these emerging cannabinoid analogs, a robust chromatographic method for the separation and quantitation of cannabinoids is presented. The method is readily adaptable to incorporate newly emerging cannabinoids as they enter the marketplace.

Methods

Target analytes. The method targeted $\Delta 9$ -THC isomers and related cannabinoid analogues, including cannabichromene (CBC), $\Delta 9$ -THC, $\Delta 8$ -THC, cannabidiol (CBD), $\Delta 6a,10a$ -THC, *exo*-THC, $\Delta 9$ -THC-P, $\Delta 8$ -THC-P, hexahydrocannabinol (HHC), $\Delta 8$ -THC-O-acetate, $\Delta 9$ -THC-O-acetate, and cannabidiol diacetate (CBD-di-O). Deuterated internal standards included CBD- d_3 , THC- d_3 , $\Delta 9$ -THC-O- d_3 , *exo*-THC- d_3 , and CBD-di-O- d_3 . Certified reference materials were obtained from commercial suppliers when available. Reference materials for cannabinoid acetate analogues were synthesized in-house from certified parent compounds by acetylation using pyridine and acetic anhydride at 75°C overnight. Conversion of parent cannabinoids to their corresponding acetate derivatives was confirmed by gas chromatography–mass spectrometry.

Calibrator preparation. Calibration curves were prepared over a concentration range of 10 to 1000 ng/mL or 1 to 100% in the products. Quality control samples were prepared at low, mid, and high concentrations of 30, 300, and 750 ng/mL or 3%, 30%, and 75% in the products, respectively, along with blank controls with internal standard (ISTD) and double blanks without ISTD. All calibrators and controls were prepared in methanol and analyzed alongside samples. Analyte concentrations were calculated by 1/x weighted linear regression based on ISTD normalized peak areas using the SCIEX [Analyst software](#).

Sample preparation. A total of 25 commercially available e-liquids, labeled as containing THC isomers and semi-synthetic cannabinoids, were purchased for analysis. For each sample, approximately 40 mg of vaping formulation was accurately weighed and diluted to a final volume of 1 mL with methanol. Samples were homogenized by agitation using a Bead Ruptor 24 (Biotage, Uppsala, Sweden). Prior to analysis, each sample was further diluted to a ratio of 1:4000 [v/v] vaping formulation to methanol.

Liquid chromatography. Chromatographic separation was performed using a [SCIEX ExionLC 2.0 system](#) equipped with a [Phenomenex Kinetex C18 column](#) (2.6 μ m, 100 Å, 150 × 3.0 mm, P/N 00F-4462-Y0). The LC was operated under isocratic conditions consisting of 25:75 [v/v] mobile phase A (water with

1 g/L ammonium formate and 0.1% (v/v) formic acid): mobile phase B [acetonitrile]. The flow rate was 0.650 mL/min, column oven set to 40°C and injection volume was 5 µL. The total runtime was 15 min.

Mass spectrometry. Samples were analyzed using a [SCIEX QTRAP 6500+ system](#) equipped with an [IonDrive Turbo V ion source](#) and an electrospray ionization (ESI) probe operated in positive ion mode. Compound-specific and ion source and gas parameters were manually optimized and are presented in **Tables 1 and 2**. Data was acquired using multiple reaction monitoring (MRM) mode with the compound-specific parameters listed in **Table 2**. Raw area counts were normalized to the deuterated analogs listed in **Table 2**.

Table 1. Source and gas parameters optimized for cannabinoid analogues analysis using the QTRAP 6500+ system

Parameter	Value
Polarity	Positive
Ion source gas 1	40 psi
Ion source gas 2	40 psi
Curtain gas	50 psi
Source temperature	600°C
Ion spray voltage	5500 V
CAD gas	Medium

Table 2. Optimized compound-specific MRM parameters and ISTD assignment for cannabinoid analysis in vaping e-liquids using the QTRAP 6500+ system. The first transition represents the quantifier MRM and the second transition is the qualifier MRM. CXP was set to 15 V and EP was set to 10 V for all transitions.

Compound	Precursor ion (m/z)	Fragment ion (m/z)	Dwell (ms)	DP (V)	CE (V)	ISTD
THCs/CBD/CBC	315	193	50	45	32	THC-d ₃ /Exo-THC-d ₃ /CBD-d ₃
	315	259	50	45	24	
CBN	311	223	50	70	29	THC-d ₃
	311	293	50	70	23	
THC-Ps	343	221	50	45	32	THC-d ₃
	343	287	50	45	24	
HHC	317	193	50	45	32	THC-d ₃
	317	261	50	45	24	
THC-d ₃ /Exo-THC-d ₃ /CBD-d ₃	318	196	50	45	32	n/a
	318	262	50	45	24	
CBD-di-O-acetate	399	315	200	70	27	CBD-di-O-acetate-d ₃
	399	357	200	70	18	
THC-O-acetates	357	315	50	50	23	THC-O-acetate-d ₃
	357	193	50	50	37	
CBD-di-O-acetate-d ₃	402	318	200	70	27	n/a
	402	360	200	70	18	
THC-O-acetate-d ₃	360	318	100	50	23	n/a
	360	196	100	50	37	

Chromatographic separation and method validation

Using the Phenomenex Kinetex C18 column and mobile phase conditions, chromatographic resolution of the isobaric compounds was achieved, including: Δ8-THC, Δ9-THC, exo-THC, CBC, and CBD; Δ8-THC-acetate and Δ9-THC-acetate; and R-hexahydrocannabinol (R-HHC) and S-hexahydrocannabinol (S-HHC), enabling reliable identification and quantitation of these closely related analytes (**Figure 2**). No carryover was observed in blank samples following injection of the highest calibrator [100% concentration], and no internal standard carryover was detected in double-blank samples across all five validation days.

A five-day validation was successfully completed for the method. Linearity was evaluated over five analytical days (n = 5), with all calibration curves demonstrating coefficients of determination (r^2) ≥ 0.9958 (**Figure 3**). Accuracy and bias were assessed using quality control samples analyzed in triplicate (n = 3) across each of the five validation days and were found to be within acceptable limits. Specifically, for the low QC, all analytes demonstrated accuracy within ±20% and precision <20%. For the mid QC, accuracy was within ±9% and precision <11% for all analytes. Finally, for the high QC, all analytes showed accuracy within ±6% and precision <11%.




Figure 2. Extracted ion chromatograms [XICs] for the targeted cannabinoid analytes in a 25 µg/mL calibration standard.




Figure 3. Calibration curves for selected cannabinoid analytes prepared between 10-1000 ng/mL [1-100% in the products]. Calibration standards were run over five days (n=5). Data shown from the quantifier MRM.

Product analysis

Analysis of the 25 commercially available e-liquids labeled as containing THC isomers and analogues revealed a wide range of cannabinoid compositions [Table 3]. Several products contained predominantly $\Delta 8$ -THC, including Bay Pineapple Express [70%], Strawberry Banana [65%], and Purple Punch [41%]. $\Delta 6a,10a$ -THC and *exo*-THC were detected in multiple samples, often alongside $\Delta 8$ -THC and $\Delta 9$ -THC. Cannabinol [CBN], a known oxidation product of THC, was present in several formulations, indicating potential product aging or thermal and oxidative degradation. Both HHC isomers were identified in eight samples and, in some cases, at appreciable total HHC concentrations [e.g., Gorilla Glue at 48% and Lucid Blue at 60%]. The THC propyl analogue, $\Delta 8$ -THC-P, was detected at low concentrations in only two products. Reports have suggested that this compound may exhibit increased potency relative to $\Delta 8$ -THC.

Acetylated cannabinoids were identified in 14 products, with $\Delta 9$ -THC-O-acetate present at higher concentrations than $\Delta 8$ -THC-O-acetate. Cannabidiol diacetate [CBD-di-O] was detected in only three of the acetylated cannabinoid formulations. **Figure 1** shows total ion chromatograms (TICs) highlighting the cannabinoid profiles in the Thai Chi and Gorilla Glue e-liquids.

The successful characterization of these complex and highly isomeric cannabinoid mixtures was enabled by the high sensitivity and selectivity of the QTRAP 6500+ system combined with the resolving power of the Phenomenex Kinetex C18 analytical column. This instrumental configuration provided sufficient chromatographic separation and mass spectrometric discrimination to resolve closely related and isobaric cannabinoid species, allowing for reliable identification and quantitation across a wide range of cannabinoid classes.

Table 3. Cannabinoid composition [%] of commercially available THC-containing e-liquids determined using the QTRAP 6500+ system.

E-liquid	CBD	Exo-THC	$\Delta 9$ -THC	$\Delta 8$ -THC	$\Delta 6a,10a$ -THC	CBN	HHC	$\Delta 9$ -THC-P	$\Delta 8$ -THC-P	CBD-di-O	$\Delta 9$ -THC-O	$\Delta 8$ -THC-O
Aurora Indica											39	2
Bay Pineapple Express		1	5	70								
Binoid Pineapple Express					15	22	14					
Binoid Skywalker OG				9							30	1
Blue Zkittlez										2	26	11
Cookies & Cream					15	10	10					
Do Si Dos										2	24	11
Fruit Loops				1							44	3
God's Gift											43	1
Gorilla Glue							48					
Hawaiian Sunrise							23					
Lava Cake				1							40	2
Lucid Blue		2		1			60					
Mowie Wowie				2						2	32	10
Natural Flavor							1					
Purple Punch	8	1		41	6	1						
SFV OG		1	2						1			
Strawberry Banana		1	2	65								
Strawberry Cough					19	20	10					
Super Harlequin				9							32	1
Super Silver Haze		1					19				18	
Thai Chi										1	25	9
THCO Oil											53	5
Train Wreck									1		38	1
White Runtz											54	1

Conclusions

This technical note demonstrated:

- An LC-MS/MS method for the separation and quantitation of 12 phyto-, semi-synthetic, and synthetic cannabinoids in vape e-liquids
- Chromatographic separation of challenging cannabinoid isomers including Δ^8 -THC, Δ^9 -THC, exo-THC, cannabichromene, cannabidiol, acetylated THC derivatives, and hexahydrocannabinol isomers using the Phenomenex Kinetex C18 column
- Reliable quantitative performance in a 5-day validation study demonstrating negligible carry-over, good calibration curve linearity and quality control (QC) accuracy and bias
- Application of the method for the characterization of cannabinoids in 25 commercial e-liquid products

Funding

This project was funded in part by National Institute of Health [P30DA033934 and T32DA007027] and National Institute of Justice 2019-MU-MU-0007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute of Justice.

References

1. Love, C.A.; Porter, N.A.; Kim, H.H.; Jaspers, I. Cannabinoid vaping products: Regulation, composition, toxicological effects, and emerging research. *Chem. Res. Toxicol.* **2025**, *38* [12], 2028–2040. DOI: [10.1021/acs.chemrestox.5c00240](https://doi.org/10.1021/acs.chemrestox.5c00240)
2. Zhang, S.; Alam, M.M.; Chandler, B.D.; Lanorio, J.P.; Deskins C.; Song, L. Potency analysis of semi-synthetic cannabinoids in vaping oils using liquid chromatography diode array detector with electrospray ionization time-of-flight mass spectrometry for confirmation of analyte identity. *Molecules* **2025**, *30* [12], 2597. DOI: [10.3390/molecules30122597](https://doi.org/10.3390/molecules30122597)
3. Holt, A.K.; Poklis, J.L.; Peace, M.R. Δ^8 -THC, THC-O acetates and CBD-di-O acetate: Emerging synthetic cannabinoids found in commercially sold plant material and gummy edibles. *J. Anal. Toxicol.* **2022**, *46* [8], 940–948. DOI: [10.1093/jat/bkac036](https://doi.org/10.1093/jat/bkac036)
4. Holt, A.K.; Karin, K.N.; Butler, S.N.; Ferreira, A.R.; Krotulski, A.J.; Poklis, J.L.; Peace, M.R. Cannabinoid-based vaping products and supplement formulations reported by consumers to precipitate adverse effects. *Drug Test. Anal.* **2023**, *15* [10], 1067–1076. DOI: [10.1002/dta.3253](https://doi.org/10.1002/dta.3253)
5. Holt, A.K.; Rudy, A.K.; Sawyer, A.N.; Poklis, J.L.; Breland, A.B.; Peace, M.R. Survey of U.S. residents and their usage of electronic cigarettes with drugs other than nicotine. *J. Psychoactive Drugs* **2024**, *56* [4], 568–577. DOI: [10.1080/02791072.2023.2250353](https://doi.org/10.1080/02791072.2023.2250353)

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product[s] not available in all countries. For information on availability, please contact your local sales representative or refer to <https://sciex.com/diagnostics>. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries [see www.sciex.com/trademarks].

© 2026 DH Tech. Dev. Pte. Ltd. MKT-39313-A



Headquarters
250 Forest Street, Marlborough,
MA 01752 USA
Phone 508-383-7700
sciex.com

International Sales
For our office locations please call the division
headquarters or refer to our website at
sciex.com/offices